Risk-Stratified and Response-Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience
Guardat en:
| Publicat a: | Advances in Hematology vol. 2025 (2025) |
|---|---|
| Autor principal: | |
| Altres autors: | , , , , , , , , , |
| Publicat: |
John Wiley & Sons, Inc.
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3236022658 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1687-9104 | ||
| 022 | |a 1687-9112 | ||
| 024 | 7 | |a 10.1155/ah/5453729 |2 doi | |
| 035 | |a 3236022658 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 100 | 1 | |a Veron, David |u Hospital Universitario Austral Pilar, Buenos Aires Argentina | |
| 245 | 1 | |a Risk-Stratified and Response-Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience | |
| 260 | |b John Wiley & Sons, Inc. |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background: The international cooperation between GATLA and AHOPCA with the support of St. Jude led to the adoption of the OEPA/COPDAC as a strategy to improve outcomes in high risk (HR) patients with HL. This study also includes the ABVD regimen for intermediate risk (IR) and low risk (LR) patients.Methods: Patients were stratified by predefined risk assignment. HR was defined as a disease in stages II B, III B, and IV. Modality treatment: LR: ABVD × 4 ± IFRT (20 Gy); IR: ABVD × 6 ± IFRT (20 Gy); and HR: OEPA–COPDAC + IFRT (20/25 Gy). The staging and response were reviewed in a periodic discussion of presentation of cases in the group. Eligibility for radiotherapy: LR patients in partial response (PR) after 4 ABVD and IR patients in PR after 2 ABVD received IFRT. All HR patients received IFRT at 20 (complete response (CR)) or 25 Gy (PR) depending on the response achieved after the first two OEPA cycles.Results: From November 2012 to June 2022, 203 pediatric patients were enrolled. A total of 171 patients were eligible in this analysis. HR: 98 patients (57.3%), IR: 52 patients (30.4%), and LR: 21 patients (12.3%). More than half of the patients were in stages III and IV and more than half also presented B symptoms. The response evaluation was performed by PET/CT in 147/171 patients (86%). A total of 68/171 patients (40%) did not received radiotherapy. Radiotherapy was omitted in 95% of the LR patients and 70% of the IR patients. The 10-year OS was 95% (90.7–97.6) for the 171 patients and 93% (85.3–96.4) for HR patients. The 10-year EFS was 91% (85.2–94.2) for the 171 patients and 87.8% (79.5–92.9) for HR patients.Conclusion: The international cooperation made it possible to significantly improve the outcomes of patients with advance disease in Argentina compared with our previous experience (7-PHD-96: COPP–ABV × 6 + IFRT Bulky Disease or PR (20/25 Gy): 5yOS: 85%, 5yEFS: 67%), reduce the number of patients who required radiotherapy, and reproduce the European experience for HR patients in a totally different context. | |
| 651 | 4 | |a Argentina | |
| 653 | |a Patients | ||
| 653 | |a Tomography | ||
| 653 | |a Abdomen | ||
| 653 | |a Lymphoma | ||
| 653 | |a Radiation therapy | ||
| 653 | |a Pediatrics | ||
| 653 | |a Lymphatic system | ||
| 653 | |a Chemotherapy | ||
| 653 | |a Biopsy | ||
| 700 | 1 | |a Streitenberger, Patricia |u Hospital Italiano de Buenos Aires Buenos Aires Argentina | |
| 700 | 1 | |a Matus, Mónica |u Grupo Argentino Para el Tratamiento de Leucemias Agudas GATLA Buenos Aires Argentina | |
| 700 | 1 | |a Pedro Negri Aranguren |u Hospital Materno Infantil San Roque Paraná Entre Ríos, Argentina | |
| 700 | 1 | |a Costa, Alejandra |u Hospital de Niños Sor María Ludovica La Plata Argentina | |
| 700 | 1 | |a Morell, Daniela |u Hospital Infantil de Córdoba Córdoba Argentina | |
| 700 | 1 | |a Terrasa, Sergio |u Departamento de Investigaciones Hospital Italiano de Buenos Aires Buenos Aires Argentina | |
| 700 | 1 | |a Castellanos, E Mauricio |u AHOPCA Unidad Nacional Oncología Pediátrica Guatemala City Guatemala | |
| 700 | 1 | |a de Alarcon, Pedro |u Department of Pediatrics University of Illinois College of Medicine Peoria Illinois, USA | |
| 700 | 1 | |a Dibar, Eduardo |u Grupo Argentino Para el Tratamiento de Leucemias Agudas GATLA Buenos Aires Argentina | |
| 700 | 1 | |a Makiya, Mónica |u Grupo Argentino Para el Tratamiento de Leucemias Agudas GATLA Buenos Aires Argentina | |
| 773 | 0 | |t Advances in Hematology |g vol. 2025 (2025) | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3236022658/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3236022658/fulltext/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3236022658/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch |